Mitchell Creem insider trades: Nutex Health (NUTX) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Mitchell reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 14, 2023 | NUTX | ↑ Buy | 50,000 | $0.43 | $21K | See note(2) | Jun 15, 2023 (1d) |
| Aug 12, 2020 | CLNH | ↑ Buy | 31,746 | $20000.00 | $634.9M | Direct | Sep 9, 2020 (28d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other NUTX insiders
Open-market trades in the last 12 months
About Mitchell Creem's insider trades
Mitchell Creem is a director at Nutex Health (NUTX). Since Aug 12, 2020, Mitchell has reported 2 open-market purchases worth $634.9M and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (8 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NUTX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.